Form 4: Cingulate EVP Acquires Shares, Warrants in Private Placement

Cingulate Inc.'s EVP and Chief Medical Officer, Matthew Brams, acquired common stock and warrants through a private placement on February 6, 2026.

Summary

• Matthew Brams, Executive Vice President and Chief Medical Officer of Cingulate Inc. (CING), acquired securities.
• The transaction occurred on February 6, 2026, as part of a private placement.
• Brams acquired 1,946 shares of Common Stock at a price of $5.04 per share.
• He also acquired 1,556 Warrants to purchase Common Stock, with an exercise price of $5.04 per share and a stated price of $0.1.
• Following these transactions, Matthew Brams beneficially owns 4,656 shares of Common Stock and 1,556 Warrants.
• The private placement was previously disclosed in a Current Report on Form 8-K filed with the SEC on January 28, 2026.
• The warrants are exercisable upon the Issuer obtaining stockholder approval of the private placement, as required by Nasdaq rules, and will expire 36 months after their exercise date.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. Insider buying by a key executive signals confidence, although the private placement itself implies a need for capital and the warrant exercisability is conditional on future stockholder approval.

Positives

• An insider, the EVP and Chief Medical Officer, acquired additional common stock and warrants, which can signal confidence in the company's future prospects.

Risks

• The exercisability of the acquired warrants is contingent upon Cingulate Inc. obtaining stockholder approval of the private placement, as mandated by Nasdaq rules.

Future Outlook

The future exercisability of the warrants acquired by the EVP and Chief Medical Officer is dependent on Cingulate Inc. securing stockholder approval for the private placement, a requirement under Nasdaq rules. This indicates a future corporate action is needed to fully realize the terms of the transaction.

Industry Context

StockSavvy.ai notes that insider purchases, such as this acquisition by a key executive, are often interpreted by the market as a signal of management's confidence in the company's future performance and valuation. While a private placement can be dilutive, an insider's participation can mitigate some concerns by demonstrating alignment of interests.

Comparison to Industry Standards

• Insider buying activity, particularly by high-ranking executives, is generally viewed positively across industries, often outperforming general market sentiment in the short to medium term.
• Private placements are a common method for companies, especially those in growth phases or with specific capital needs, to raise funds outside of public offerings. The terms, including warrant coverage and pricing, are typically benchmarked against prevailing market conditions and the company's risk profile.

Corporate Governance

Related Party Transactions

• Matthew Brams, an Executive Vice President and Chief Medical Officer, acquired common stock and warrants from Cingulate Inc. as part of a private placement.

Stakeholder Impact

• Shareholders: Potential for increased confidence due to insider buying, but also potential for dilution from the private placement. The requirement for stockholder approval provides a mechanism for shareholder input.
• Management (Matthew Brams): Increased equity stake aligns interests with shareholders, subject to warrant exercisability.

Next Steps

• Cingulate Inc. must obtain stockholder approval for the private placement to allow the acquired warrants to become exercisable, as required by Nasdaq rules.

Key Dates

Keywords

Cingulate Inc., CING, Form 4, Insider Transaction, Private Placement, Common Stock, Warrants, Matthew Brams, Equity Acquisition